Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Clinical Trials

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Phase 3

Conditions: EGFR Gene Mutation

Interventions: Drug: pemetrexed
Drug: cisplatin
Drug: Erlotinib

First Posted Date: 2016-09-01

Last Posted Date: 2016-09-01

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT02886195

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2016-05-17

Last Posted Date: 2016-08-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 264

Registration Number: NCT02774278

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Phase 3

Terminated

Conditions: Carcinoma, Non-small Cell Lung

Interventions: Drug: Docetaxel
Drug: Erlotinib

First Posted Date: 2016-05-17

Last Posted Date: 2019-04-30

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02775006

Locations: 🇳🇱
VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands
🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱
Laurentius Hospital, Roermond, Netherlands

and more 16 locations

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Phase 2

Terminated

Conditions: Epidermal Growth Factor Receptor
Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2016-05-12

Last Posted Date: 2019-11-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT02770014

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States